Compare Stocks

H2O Innovation Inc. designs and provides integrated water treatment solutions based on membrane filtration technology. It operates through three segments: Water Technologies and Services, Specialty Products, and Operation and Maintenance Services. The company offers membrane filtration technology for municipal, industrial, energy, and natural resources end-users; and aftersales services, as well as digital solutions to monitor and optimize water treatment plants. Its products include the FiberFlex open-source technologies for water treatment systems; the flexMBR for wastewater treatment systems; SILO system for wastewater and water reuse treatment; and FlexBox, a mobile fleet of water and wastewater treatment systems, such as containerized ultrafiltration or reverse osmosis (RO) systems. The company also offers specialty chemicals, consumables, and specialized products for the water industry, including RO membrane chemicals, such as antiscalants, flocculants, biocides, and cleaning chemicals; corrosion resistant equipment for desalination plants; flexible grooved-end couplings, fiberglass reinforced polyester cartridge filter housings, self-cleaning disc and screen filters, bag filters, cartridges, and strainers; and maple farming equipment. In addition, it operates, maintains, and repairs water and wastewater treatment systems, distribution equipment, and associated assets. The company was incorporated in 1995 and is headquartered in Quebec City, Canada. As of December 8, 2023, H2O Innovation Inc. was taken private.

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The company's laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; and technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture. It sells its products primarily through dealers, its subidiaries, and a national distributor. The company was founded in 1906 and is headquartered in Statesville, North Carolina.

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.